MIAMI--(BUSINESS WIRE)--Jan. 19, 2006--DOR BioPharma, Inc. ("DOR" or the "Company") (AMEX:DOR), today announced that it has entered into a common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago based institutional investor, whereby Fusion Capital shall buy up to $6.0 million of the Company's common stock. These funds are expected to be used for general corporate purposes including the filing of its NDA for orBec(R). Under the common stock purchase agreement, funding of the $6,000,000 shall occur from time to time over a 15 month period after the Securities & Exchange Commission ("SEC") has declared effective a registration statement covering the shares of common stock to be purchased by Fusion Capital. Each month during the term of the agreement, DOR has the right to sell to Fusion Capital up to $400,000 of its common stock at a price based upon the market price of the Company's common stock on the date of each sale without any fixed discount to the market price. The Company has the right to control the timing and the amount of stock sold to Fusion Capital and under certain conditions may increase or decrease the amount of stock sold to Fusion Capital. The Company also has the right to terminate the agreement at any time.
